Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring aBRCA1orBRCA2Gene Alteration

14 Aug 2020

Abstract excerpt

PURPOSE BRCA1 or BRCA2 ( BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study. METHODS We enrolled patients who progressed after one to two lines of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32795228
DOI: 10.1200/jco.20.01035

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring aBRCA1orBRCA2Gene AlterationPMID 32795228Read ↗

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudySemantic proximity Read ↗

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analysesSemantic proximity Read ↗

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.Semantic proximity Read ↗

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudySemantic proximity Read ↗

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes.Semantic proximity Read ↗

Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.Semantic proximity Read ↗

TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutationsSemantic proximity Read ↗

Olaparib for Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.Semantic proximity Read ↗

PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.